SP Elixir (OPC) Private Limited

Bortlieva 2mg Injection is an anti-cancer medication. It works by blocking or slowing the breakdown of proteins in cancer cells.

Bortero 2mg Injection contains Bortezomib, a proteasome inhibitor used primarily in the treatment of certain types of cancer, specifically multiple myeloma and mantle cell lymphoma. Bortezomib works by inhibiting the proteasome, a complex within cells that breaks down proteins. By blocking the proteasome, Bortezomib leads to the accumulation of damaged proteins within cancer cells, which ultimately induces cell death and prevents the cancer cells from growing.

Bortero 2mg Injection is commonly used for:

• Multiple myeloma: A type of blood cancer affecting plasma cells.
• Mantle cell lymphoma: A type of non-Hodgkin lymphoma.

It is typically administered intravenously (IV) or subcutaneously (under the skin), depending on the specific treatment protocol and individual patient needs.

Common side effects of Bortezomib include:

• Fatigue
• Nausea and vomiting
• Diarrhea
• Peripheral neuropathy (nerve damage causing tingling, numbness, or pain, especially in the hands and feet)
• Low blood cell counts (leading to an increased risk of infections, anemia, and bleeding)
• Fever
• Low blood pressure

In some cases, more serious side effects may occur, such as:

• Heart problems (including heart failure)
• Liver damage
• Severe infections due to low white blood cell counts

Before starting treatment, patients are monitored for blood counts, liver function, and other parameters to help manage side effects. Due to the risk of peripheral neuropathy, it's important for patients to report any signs of nerve damage early.

Bortezomib is often used in combination with other chemotherapy drugs, and the treatment regimen typically includes cycles of therapy with rest periods in between.

As with all chemotherapy treatments, regular follow-ups with a healthcare provider are necessary to monitor treatment response and manage any side effects.

Bortezomib 3.5 mg injection